DorsaVi Ltd, a health care biotechnology company based in Melbourne East, Australia, continues to operate within the niche of wireless sensor movement monitoring systems. The company’s primary focus is on the development and sale of technology designed to monitor workplace and sports-related injuries and pain. DorsaVi’s offerings are particularly relevant in environments where real-time monitoring of physical activity can prevent injuries and manage pain effectively.
As of the latest trading session on March 2, 2026, DorsaVi’s stock closed at A$0.027 on the ASX All Markets stock exchange. This price is notably modest compared to the 52-week high of A$0.069 achieved on October 6, 2025, and significantly higher than the 52-week low of A$0.006 recorded on April 9, 2025. The company’s market capitalization stands at A$32,670,000, reflecting its current valuation in the market.
Financially, DorsaVi trades at a negative price-to-earnings (P/E) ratio of -5.4, indicating that the company is currently not generating profits. This negative P/E ratio suggests that the company’s earnings are below zero, which is not uncommon for companies in the biotechnology sector that are heavily invested in research and development. Additionally, the price-to-book ratio of 5.47 implies that the market values DorsaVi at approximately five and a half times its book equity, highlighting investor confidence in the company’s future potential rather than its current financial performance.
A significant development for DorsaVi occurred in November 2025, when the company secured a leading process-in-memory neuromorphic IP license. This acquisition is a strategic move that could potentially enhance DorsaVi’s technological capabilities and market position. However, since this announcement, there have been no new public disclosures, leaving investors and stakeholders with limited updates on the company’s progress and future plans.
Overall, DorsaVi’s valuation appears to be driven more by its future intellectual property prospects than by its current profitability. The company’s share price has remained within a relatively tight historical range, reflecting a cautious market sentiment. For more detailed information about DorsaVi Ltd and its offerings, interested parties can visit the company’s website at www.dorsavi.com .
